Introduction
============

In the last 5 years many clinical studies have demonstrated that imatinib, the first tyrosine kinase inhibitor introduced in the treatment of chronic myeloid leukemia (CML) (Olsson-Stromberg et al) has high level of activity, low toxicity, and ongoing durability ([@b11-btt-1-121]; [@b35-btt-1-121]; [@b1-btt-1-121]; [@b25-btt-1-121]). Its efficacy is mainly observed in newly diagnosed patients with chronic phase CML, where complete hematological and cytogenetic responses where achieved in about 98% and in more than 80% of cases, respectively ([@b21-btt-1-121]; [@b34-btt-1-121]; [@b27-btt-1-121]). The findings of the 5-year update of the International Randomised Study of Interferon versus STI571 (IRIS) comparing the efficacy of imatinib 400 mg/day with interferon-alpha (IFNα) + ara-c in newly diagnosed patients with chronic phase CML showed an estimated rate of complete cytogenetic response (CCR) of 87% and an overall survival rate of 89% at 60 months ([@b10-btt-1-121]). With similar follow-up for patients initially studied in "late chronic phase" disease with intolerance or failure during prior IFN, CCR was achieved in 53%, reflecting the remarkable ability of imatinib to salvage such patients ([@b22-btt-1-121]). Although the rates of progression for patients with chronic phase CML treated with imatinib remain low, a subset of patients develops resistance to this drug. The most common mechanism of resistance is the expansion of a clone of leukemic cells with a mutation in the kinase domain of Bcr-Abl ([@b4-btt-1-121]; [@b42-btt-1-121]; [@b46-btt-1-121]; [@b3-btt-1-121]). This mutant clone is partially or totally imatinib resistant because of the reduced capacity to imatinib to bind to the mutant Bcr-Abl protein. Therapeutic options in cases of imatinib resistance include increasing the dose of imatinib, switching to a second generation Abl kinase inhibitor and proceeding to an allogenic stem cell transplant. In this review, we focus on the characterization of nilotinib, a novel, oral tyrosine kinase inhibitor developed from its parent compound, imatinib, and we discuss its current status in clinical trials.

Mechanisms of imatinib resistance
=================================

Depending on the time of onset, two categories of resistance can be distinguished: if there is no response after initial treatment, resistance is described as *primary* or intrinsic, in contrast, *secondary* or extrinsic resistance refers to loss of a previously established response ([@b18-btt-1-121]). The rate of all progression events, including hematologic and cytogenetic relapse within chronic phase and transformation to advanced phase is 18% after a median of 5 years ([@b32-btt-1-121]). Although the molecular mechanisms responsible for the rare cases of primary resistance remain poor, the mechanisms of secondary resistance are largely understood. In the majority of cases, resistance is caused by reactivation of BCR-ABL tyrosine kinase activity due to the emergence of specific point mutations within several critical regions of the Abl kinase domain ([@b20-btt-1-121]; [@b44-btt-1-121]; [@b5-btt-1-121]; [@b45-btt-1-121]). Such mutations impair imatinib binding either by affecting critical contact residues or by inducing a BCR-ABL conformation to which imatinib is unable to bind. More than 40 different point mutations encoding for distinct single amino acid substitutions in the Bcr-Abl kinase domain have been identified in relapsed CML patients. Different mutants seem to have different degrees of resistance to imatinib: in vitro data indicate that while some mutations might be overcome by dose escalation ([@b36-btt-1-121]), others confer a highly resistant phenotype, thereby suggesting withdrawal of imatinib in favor of alternative therapeutic strategies. Indeed, since resistance often coincides with reactivation of the kinase activity within the leukemic clone, either Bcr-Abl itself or Bcr-Abl-triggered downstream signaling pathways remain good targets for molecular therapy.

Mechanisms of imatinib resistance that do not involve ABL mutations but are clinically relevant include amplification of the BCR-ABL fusion gene, transcriptional overexpression of Bcr-Abl, increased multi-drug resistance (MDR) activity ([@b31-btt-1-121]; [@b50-btt-1-121]), cytogenetic progression, or possible the involvement of other kinases including members of the Src family ([@b9-btt-1-121]; [@b28-btt-1-121]). In patients who achieve a deep reduction in leukemic-cell burden, BCR-ABL transcripts rarely become undetectable and the disease recurs in most of these patients if imatinib is discontinued. This persistence of a molecularly detectable leukemic population is due to CML "stem cell resistance", based in the ability of CML progenitors to exchange between a cycling and resting or "quiescent" state, the latter associated with minimal or no BCR-ABL expression and resulting lack of effect of Abl kinase inhibitors ([@b15-btt-1-121]).

Looking behind imatinib: nilotinib, a novel inhibitor of BCR-ABL
================================================================

The emergence of imatinib resistance has stimulated the development of new kinase inhibitors that are able to overcome or prevent the development of mechanisms of failure and ultimately eliminate all evidence of disease. Two of these inhibitors are in phase II trials: dasatinib (formerly BMS-354825, Spricel^®^) ([@b30-btt-1-121]; [@b47-btt-1-121]; [@b8-btt-1-121]; [@b19-btt-1-121]; [@b41-btt-1-121]) and nilotinib (formerly AMN-107, Tasigna^®^). Other inhibitors (SKI-606, VX-680) ([@b14-btt-1-121]; [@b7-btt-1-121]; [@b13-btt-1-121]; ) are currently in phase I trials.

Nilotinib was developed by researchers at Novartis Pharmaceuticals using a rational drug design strategy based on the replacement of the metylpiperazinyl group of imatinib and optimization of drug-like properties ([Figure 1](#f1-btt-1-121){ref-type="fig"}).

Like imatinib, nilotinib does not inhibit Src kinase and binds only to the inactive conformation of Bcr-Abl, with P-loop folding over the ATP-binding site, and the activation-loop blocking the substrate binding site, to disrupt the ATP-phosphate-binding site and inhibit the catalytic activity of the enzyme ([@b49-btt-1-121]). Nilotinib makes 4 hydrogen-bond interactions with the Abl kinase domain, involving the pyridyl-N and the backbone-NH of Met318, the aniline-NH and the side chain hydroxyl of Thr315, the amido-NH and side chain carboxylate of Glu286, as well as the amido-C==O of Asp381 and a fluorine atom in the trifluoromethyl group of nilotinib ([@b49-btt-1-121]). This close interaction made changes in the core of imatinib prohibitive. The improvement in binding affinity for Bcr-Abl maintains the ability to inhibit also Kit and PDGFR, but with less affinity of imatinib (Bcr-Abl \> PDGFR \> Kit).

Preclinical studies
===================

Nilotinib is approximately 30-fold more sensitive than imatinib in the killing of BCR-ABL-dependent cells derived from patients with CML (K562 and Ku-812F cells) and cell lines (32D and baF3), and it is active against 32/33 imatinib-resistant cell lines with BCR-ABL mutations. The sensitivity of Bcr-Abl mutants to AMN107 can be summarized into 4 categories: high (IC~50~ ≤ 70 nmol/L: M244V, G250E, Q252H, F3llL, F317L, M351T, V379I, L387M, H396P, H396R), medium (IC~50~ ≤ 200 nmol/L: Y253F, E255K, F359V), low (IC~50~ ≤ 450 nmol/L: Y253H, E255V), and insensitive (IC~50~ \>2 μmol/L: T315I) ([Table 1](#t1-btt-1-121){ref-type="table"}) ([@b36-btt-1-121]). Nilotinib does not inhibit T315I (also resistant to imatinib and dasatinib), due to the loss of the hydroxyl side chain and the introduction of the methyl group of the isoleucine in the "gatekeeper" region of the ATP binding site, which inhibits binding ([@b40-btt-1-121]). On the other hand, M351I is more sensitive to nilotinib than would be predicted. This residue makes close contact with imatinib, but not with nilotinib, due to the differences in their chemical structure. Therefore, M351I affects the binding of imatinib, but has little effect on the binding of nilotinib ([@b37-btt-1-121]) ([Table 1](#t1-btt-1-121){ref-type="table"}). In vivo studies demonstrated that nilotinib increased survival in mouse models with native Bcr-Abl and imatinib-resistant Bcr-Abl ([@b16-btt-1-121]). Nilotinib is also approximately 30--40 times more potent than imatinib in inhibiting the proliferation of p190 Bcr-Abl -- expressing Ph-positive ALL cell lines and it is also consistently (more than 20 times) more potent than imatinib in inhibiting phosphorylation of p190 Bcr-Abl kinase in these cell lines ([@b48-btt-1-121]).

Phase I study
=============

In a dose-escalating phase I study ([@b24-btt-1-121]), nilotinib was administered orally to 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (ALL) according to the following dosing schedule: 50 mg (7 patients), 100 mg (7), 200 mg (10), 400 mg (10), 600 mg (6), 800 mg (19), and 1200 mg (10) or to receive 400 mg twice daily (32) or 600 mg twice daily (18). Plasma level saturation was observed at more than 400mg/day. Among 119 patients, 17 were in chronic phase disease, 56 in accelerated phase (10 with clonal evolution only), 24 in myeloid blast phase, 9 in lymphoid blast phase, and 13 had Ph-positive ALL. Significant clinical activity was identified in all CML phases. Overall, of 33 patients with the blastic phase, 13 had a hematologic response to nilotinib (39%) and 9 patients (27%) had a cytogenetic response, 6 of whom had a major cytogenetic response (Ph-positive cells in metaphase, ≤35%). Of 46 patients with accelerated-phase CML (excluding those with clonal evolution only), 33 had a hematologic response and 22 had a cytogenetic response; 9 of these responses were major. Among the 10 patients who had clonal evolution as the only feature of the accelerated phase of CML, 5 had active disease and 5 were in complete hematologic remission. All 5 patients with clonal evolution and hematologic disease had a complete hematologic response; 6 of 10 had a major cytogenetic response. Among 17 patients with the chronic phase of disease, 11 of 12 patients with active disease have had a complete hematologic remission. There were cytogenetic responses in 9 of 17 patients who could be evaluated, including 6 responses that were complete. One of 10 patients with Ph-positive ALL (hematologic relapse) had a partial hematologic response, and 1 of 3 patients with Ph-positive ALL and persistent molecular signs of ALL had a complete molecular remission ([Table 2](#t2-btt-1-121){ref-type="table"}). Response rates to nilotinib were similar in patients with and those without BCR-ABL mutations. Two patients with a mutation of T315I did not have a response to nilotinib, as predicted from preclinical studies.

The treatment was well tolerated. Most frequent grade 3--4 adverse events were hematologic, with thrombocytopenia and neutropenia seen in 20% and 12%, respectively.

Other adverse events were less frequent and were primarily grade 1--2. Neutropenia and indirect self-limited reversible hyperbilirubinemia were observed mostly at the dose of 600 mg twice daily. A nilotinib dose of 400 mg twice daily was selected for the phase II studies based on efficacy and long-term side effects ([@b23-btt-1-121]). Nilotinib prolongs the QTcF interval in some patients. One unexplained sudden death was reported beyond the follow-up time analysis ([@b24-btt-1-121]). This finding indicates the need for careful monitoring for cardiac events and arrhythmias in all patients who are receiving nilotinib and a strict avoidance of medications that may prolong the QTcF interval.

Phase II studies
================

The phase II study was designated to evaluate the safety and efficacy, as defined by hematologic (normalization of white blood cell counts) and cytogenetic (reduction or elimination of the Ph+ chromosome) response rates of nilotinib administered to imatinib-resistant or intolerant patients with Ph+ CML in chronic phase, accelerated phase, blastic phase and Ph-positive ALL. The 316 chronic-phase patients in the phase II study were heavily pre-treated for Ph+ CML, with a significant majority (72%) having received at least 600 mg of imatinib as well as having been treated earlier with interferon (65%) and hydroxyurea (83%).

Among 279 assessable patients (ie, those patients with at least six months of follow up) with chronic-phase disease, major cytogenetic response was observed in 145 (52%) of which 96 (34%) were complete. Complete hematologic response was reported in 137 (74%) of 185 assessable patients. In patients with at least 10 months follow-up, the median time to cytogenetic response was 2.8 months (range 1--11), and the median time to complete hematologic response was 1.0 (range 1--8) months ([@b12-btt-1-121]; [@b29-btt-1-121]).

Among 64 patients with accelerated-phase disease, major cytogenetic response was observed after at least 8 months follow-up in 23 patients (36%), of which 14 (22%) were complete. Confirmed hematologic response occurred in 38 (59%), of which 15 (23%) were complete. The median time to cytogenetic response was 2.0 months (range 1--8), and the median time to complete hematologic response was 1.0 (range 1--3) months ([@b26-btt-1-121]).

Preliminary data have also been presented for 96 blast phase and 34 Ph-positive ALL patients. Complete hematological response was reported in 12 (13%) blast phase patients, marrow response in 6 (6%), return to chronic phase and stable disease in 17 (18%) patient each. Complete responses were reported in 2 (6%) Ph+ ALL patients (1 relapsed/refractory and 1 with minimal residual disease) ([Table 3](#t3-btt-1-121){ref-type="table"}) ([@b39-btt-1-121]).

The phase II study showed an acceptable tolerability profile with a low incidence of events related to fluid retention such as edema, a side effect common with other tyrosine kinase inhibitors. The most frequent Grade 3 or 4 adverse events were primarily hematological in nature and include neutropenia and thrombocytepenia. Elevations were seen in bilirubin, liver function tests, lipase enzymes, and blood sugar, which were mostly transient and resolved over time. These cases were easily managed and rarely led to discontinuation. Pancreatitis was reported in less than 1% of cases. The study also showed virtually no non-hematologic cross-intolerance between imatinib and nilotinib (cross-intolerance occurs when patients cannot tolerate two different drugs because of the same side effects). Causes of non-hematologic intolerance to imatinib, which occurred in 95 patients, included Grade 3 or 4 rash/skin toxicity, fluid retention, gastrointestinal intolerance, liver toxicity, and myalgia/arthralgia. When treated with nilotinib, none of these patients experienced severe rash/skin toxicity, fluid retention or myalgia/ arthralgia. One patient each experienced severe gastrointestinal intolerance and liver toxicity. Further follow-up of the phase II studies is ongoing.

Nilotinib as first-line therapy
===============================

Based on Phase II experience, a study of nilotinib as first line therapy for patients with CML in early chronic phase has been started with the objective to improve the overall molecular response and to achieve responses earlier since early achievement of response has been correlated with improved long-term outcome. The preliminary data in 14 patients treated suggest that indeed the higher potency is translating into better responses, with 100% of patients in complete hematologic response after 3 months of therapy, and 100% of patients in complete cytogenetic response within 6 months. A major molecular response was achieved in 54% by 6 months. These responses appeared to be more rapid than observed with imatinib 800 mg daily ([@b23-btt-1-121]).

In addition, considering the efficacy of nilotinib after failure to imatinib, there is interest in exploring earlier intervention in patients who have not met the criteria for failure but have a suboptimal response as defined by the recommendations of a panel of CML experts ([@b2-btt-1-121]).

Future strategies
=================

There is an urgent need for the development of compounds active against the T315I-Bcr-Abl mutant because it might drive the majority of cases who acquire resistance to novel second-generation inhibitors. The T315I is responsible for approximately 15% of the cases of relapse in CML and Ph+ ALL patients on imatinib therapy. Structural analyses indicate that the substitution of threonine with isoleucine at residue 315 eliminates a crucial hydrogen-bonding interaction and introduces a steric clash which abrogates binding and effective inhibition of Bcr-Abl by imatinib as well as by several novel inhibitors ([@b40-btt-1-121]). A different approach to tyrosine kinase inhibition is to design inhibitors binding regions of Bcr-Abl other than the ATP binding pocket. This is the case of ON012380 ([@b17-btt-1-121]), which binds to the substrate binding site. ON01910 is a similar agent that also inhibits Plk1, a kinase that plays a critical role in cell cycle progression. Adaphostin is a non-ATP competitive TKI that inhibits Bcr-Abl and induces apoptosis in both imatinib-sensitive and imatinib-resistant cell lines and acts synergistically with imatinib. Adaphostin also increases levels of intracellular reactive oxygen species and can stimulate apoptosis in Ph-negative malignant cells ([@b33-btt-1-121]).

An intriguing alternative is to explore the possibility of whether molecules that have been developed as inhibitors for other protein kinases and are already undergoing clinical trials might inhibit the T315I-Bcr-Abl mutant. MK-0457 (VX-680) is a potent multikinase inhibitor with activity against aurora kinases ([@b6-btt-1-121]; [@b43-btt-1-121]). The biochemical structure of MK-0457 makes it able to bind and inhibit Bcr-Abl kinase despite the presence of T315I mutation that prevents the inhibitory activity of all other kinase inhibitors tested in the clinic including imatinib, dasatinib and nilotinib. A phase I study of MK-0457 is being conducted and the preliminary analysis has shown responses in some of the patients with CML who had failed imatinib and had the T315I mutation, as well as patients with myeloproliferative disorders with the JAK-2 mutation. Phase II studies of this agent, with particular attention to these patient populations, are starting ([@b13-btt-1-121]).

Conclusion
==========

Since Bcr-Abl signaling remains central to CML pathogenesis, the selective inhibition of wild type and imatinib resistant Bcr-Abl signaling is still the therapeutic strategy of choice to overcome imatinib resistance. This approach led to the development of novel tyrosine kinase inhibitors more potent than imatinib, such as dasatinib and nilotinib. Preclinical and early-phase clinical findings indicate that nilotinib, a "cousin" of imatinib, may be useful in the treatment of imatinib-refractory CML, due to its strong binding affinity to Abl, its activity against imatinib-resistant BCR-ABL mutants and its efficacy and tolerability in clinical studies. However, the durability of responses remains undefined. Furthermore, nilotinib (like imatinib and dasatinib) do not overcome the T315I-Bcr-Abl mutation, which may drive the majority of acquired resistance cases to these compounds. Strategies to override resistance mediated by the T315I mutation represent the next major goal in the targeted treatment of CML. Compounds such as VX-680, an aurora kinase inhibitor, capable of binding to and inhibiting kinase activity of the T315I-Bcr-Abl mutation, are very encouraging.
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###### 

Comparison between imatinib, nilotinib IC~50~ values (nmol/L) for cellular proliferation and cellular Bcr-Abl tyrosine phosphorylation assay

               Ba/F3 cellular assays                       
  ------------ ----------------------- --------- --------- ---------
  WT Bcr-Abl   260                     280       13        10
  M244V        2,000                   500       38        8
  G250E        1,350                   1,000     48        7
  Q252H        1,325                   1,500     70        15
  F311L        480                     600       23        44
  F317L        1,050                   400       50        47
  M351T        880                     500       15        8
  V397I        1,630                   800       51        15
  L387M        1,000                   2,700     49        33
  H396P        850                     2,700     41        70
  H396R        1,750                   1,000     41        22
  Y253F        3,475                   4,200     125       55
  E255K        5,200                   5,000     200       70
  F359V        1,825                   3,100     175       43
  Y253H        \>6,400                 \>5,000   450       155
  E255V        \>6,400                 \>5,000   430       250
  T315I        \>6,400                 \>5,000   \>2,000   \>5,000

###### 

Results from a phase I study: response to nilotinib in patients with imatinib resistance

  Disease phase                Patients   Hematological response   Cytogenetic response        
  ---------------------------- ---------- ------------------------ ---------------------- ---- ----
  Chronic phase CML            17         92                       92                     53   35
  Accelerated phase CML                                                                        
  Hematological disease        46         72                       46                     48   20
  Clonal evolution only        10         100                      100                    90   60
  Myeloid blastic phase CML    24         42                       8                      29   21
  Lymphoid blastic phase CML   9          33                       0                      22   11

**Abbreviations:** CML, chronic myeloid leukemia.

###### 

Results from a phase II study: response to nilotinib in patients with imatinib failure

  Disease phase           Patients   Hematological response   Cytogenetic response
  ----------------------- ---------- ------------------------ ----------------------
  Chronic phase CML       279        74                       52
  Accelerated phase CML   64         23                       36
  Blast phase CML         96         13                       NA
  Ph-positive ALL         34         6                        NA

**Abbreviations:** ALL, acute lymphoblastic leukaemia; CML, chronic myeloid leukemia; NA, not available.
